71,72 Antiplatelet therapy seems to be BGJ398 effective in reducing atherosclerosis velocity by inhibiting both the first and second phases of atherosclerosis.73 Anti-inflammatory effects of antiplatelet medication are effectual in atherosclerosis velocity reduction by decreasing the volume of atherosclerosis

plaques.73 Also, antiplatelet therapy through inhibiting the adverse effects of activated platelets can indirectly raise Inhibitors,research,lifescience,medical the stability status of plaques73 and subsequently lessen atherosclerosis velocity. Decreased inflammatory process in atherosclerosis plaques also directly leads to increased plaque stability.16 However, the effect of time-related reduction on antiplatelets should be clarified in future studies. All previous investigations have focused only on the probability of plaque regression at the expense of almost neglecting the imperative parameter Inhibitors,research,lifescience,medical of time. We recommend that future studies be designed based on the probable association between statin therapy and atherosclerosis velocity reduction. Conclusion We proposed a new concept in the field of atherosclerosis by suggesting the term “atherosclerosis velocity”, which encompasses all the three essential parameters of volume of plaque, time/ duration of plaque progression, and/or acute rupture and plaque stability. Our review article reveals that the previous studies have Inhibitors,research,lifescience,medical not sufficiently probed into

these three parameters. Inhibitors,research,lifescience,medical We believe if the concept of atherosclerosis velocity is applied in further experiments, especially in experimental models, we can expect a practical curve of atherosclerosis. Conflict of Interests: None declared.
Megaloblastic

anemias are a group of disorders characterized by peripheral blood cytopenia(s) resulting due to ineffective hematopoiesis Inhibitors,research,lifescience,medical in the marrow. They are usually caused by nutritional deficiencies (most common) of either vitamin B12 or folate; or both, inherited disorders of DNA synthesis, or following certain drug therapy.1 Pyrexia in megaloblastic anemia, albeit well known, is rarely characterized. However, megaloblastic anemia, solely as the cause of pyrexia, can be found in only a small proportion of cases, for which differentiation from fever of unknown origin (FUO) may be difficult even after exhaustive laboratory investigations.2-8 The aim of the present article was to highlight this aspect of megaloblastic anemia with a brief review of the existing literature and create awareness very among practicing physicians about a treatable condition. Case Presentation A 51 year old lady, vegetarian, presented to the General Medicine Outpatient Department of Pondicherry Institute of Medical Sciences, Puducherry, India, with complaints of fever, nausea with vomiting, and burning micturition of 3 days’ duration. The fever was on and off, moderate grade, and not associated with chills and rigors. She had easy fatigability with loss of weight and appetite.